The concept that has emerged over the past century suggests that macrophages represent an evolutionarily ancient, dispersed, homeostatic system, on a par with the nervous and endocrine systems … Macrophages are essential for survival and provide an attractive target to manipulate the host, for both immunologic and metabolic purposes.
Metastases cause 90% of cancer deaths worldwide. In most cases, this is because metastatic tumour cells become resistant to therapy and develop methods to evade immune responses. Resistance to cancer treatment can be intrinsic to the tumour cells, but it is often conferred by non-malignant cells that make up the tumour microenvironment (TME). The TME is composed of tissue-resident cells and a large proportion of recruited immune cells that, in certain solid tumours such as breast cancer, can constitute up to 50% of the tumour mass. Original theories assumed that these immune cells were part of the body's response to reject tumours. Indeed, it is still proposed that, at the earliest stage of tumour onset, the immune system reacts to the presence of cancer by activating T cells and macrophages, which clear the tumour and reduce the incidence of cancer 1 .
However, once tumours progress past this initial state, the immune TME is modified to support the tumour and promote its progression while suppressing any immune cell-mediated cytotoxicity 2 . In this process, substantial clinical and experimental evidence indicates that macrophages -present abundantly in most tumour types -have a major regulatory role in promoting tumour progression to malignancy 3 . Tumour-associated macrophages (TAMs), at least in mouse models, largely originate from bone marrow monocytes that are recruited through inflammatory signals released by cancer cells in the primary and metastatic tumour, where they differentiate into TAMs and facilitate tumour progression 4, 5 . However, in cancers such as gliomas and those of the pancreas, TAMs can also derive from erythro-myeloid progenitors (EMPs) developed in the yolk sac at the embryonic stage [6] [7] [8] 
. Nevertheless, in either case, the TME promotes differentiation of these progenitors to new tumourassociated phenotypes that vary depending on their location in the tumour but are generally pro-tumoural.
Several strategies in immuno-oncology have been developed in the past few years to reactivate the adaptive and innate immune systems to mount a robust antitumoural immune response as an alternative approach to classic anticancer treatments, to which tumours generally develop resistance. Clinical trials with immune
Box 1 | Macrophage lineage and TAM origin redefined
The understanding of the origins of macrophages has recently undergone a profound shift owing to the use of modern lineage tracing techniques. These methods use inducible Cre recombinases expressed from cell-specific promoterssuch as the inducible Csf1r-iCre/Esr1 mouse crossed with floxed, coloured reporter mice -that permanently tag progeny cells at specific times in development. These methods, together with single-cell and bulk RNA sequencing, have allowed precise developmental origins of macrophages to be ascertained. A revelation in these studies is that most tissue-resident macrophages are not derived from bone marrow progenitors, as previously thought, but instead from the yolk sac or fetal liver 270, 271 . Detailed lineage tracing has indicated that macrophages originate from at least three different embryonic sources (from erythro-myeloid progenitor (EMP) in the yolk sac and fetal liver, and from macrophage/dendritic cell progenitor cells (MDPs) in the bone marrow) and differentiate into tissue-specific macrophages according to their origin, or to other cell types (such as common dendritic cell progenitors (CDP; see the figure) 272, 273 . Some tissue-specific macrophages in adults are almost exclusively derived from one source (such as those in the brain, which are derived from yolk sac, and those in the intestine, which are derived from bone marrow), while in other tissues -such as the skindifferent proportions of macrophages derive from one source or another. In some tissues, such as heart, the yolk sacderived macrophages are replaced from fetal liver monocytes (however, see REFS 269, 271 for different lineage interpretations) 271, 274, 275 . The presence of persistent embryonic populations throughout life in most tissues suggests that these tissues harbour pre-macrophages (pMACs) that can proliferate to give rise to mature macrophages 275 . These data have also revealed different regulatory mechanisms; for example, bone marrow-derived cells require transcription factor cMYB, which is not required for yolk sac-derived macrophages 270 . Nevertheless, the dominant transmembrane receptor controlling the differentiation and survival of almost all macrophages regardless of their origins is the colony-stimulating factor 1 receptor (CSF1R). In its absence, almost all macrophages are dramatically depleted in mice, with some notable exceptions such as the lung, in which they are regulated by CSF2 (REF.
276
). However, it should be recognized that in addition to this requirement for CSF1R there are tissue-specific growth factors and chemokines as well as microenvironmental cues that specify macrophage local identity 277 . These observations open a number of intriguing questions, for example, about the importance of the phenotype of macrophages according to their lineage compared with their tissue environment, whether the replacement of yolk sac-derived or fetal liver-derived macrophages with bone marrow-derived macrophages results in identical phenotypes and whether macrophages from different origins can be individually targeted. In the context of tumours, these questions are important because, although in many mouse models most TAMs seem to be of bone marrow origin, there are several exceptions such as in models of pancreatic cancer and glioma, in which the populations are a mixture of fetal liver-derived and bone marrow-derived macrophages 7, 8 . For example, in pancreatic cancer models, it is the yolk sac-derived macrophages but not the bone marrow-derived macrophages that are pro-tumoural, suggesting that origin is important 57 . These different origins might be of clinical relevance, as they could allow independent targeting of subpopulations 6 . It also raises questions as to whether inhibition of bone marrow-derived macrophage recruitment might result in compensation by yolk sac-derived and/or fetal liver-derived tissue progenitors or vice versa. Such observations again emphasize the importance of understanding macrophage origin, heterogeneity and dynamics in the tumour microenvironment.
Figure adapted from REF.
183
, Springer Nature Limited. Patrolling checkpoint inhibitors (such as monoclonal antibodies (mAbs) against cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and PD1 ligand (PDL1) that potentiate the activity of cytotoxic CD8 + T cells) have shown success in the treatment of cancers such as melanoma and lung cancer. However, in most cases, only a small fraction of patients fully respond to immunotherapy for unknown reasons 9 . In mouse models, TAMs promote the recovery of tumours from biologic therapies, chemotherapies and radiotherapies through a mixture of activities that include promotion of angiogenesis, maintenance of stem cells and inhibition of immune responses 10 . In some tumours, macrophage infiltration also interferes with efficacy of immunotherapy, neutralizing efforts to reactivate CD8 + T cells. For this reason, several therapeutic strategies to modulate TAM function, infiltration or activation are emerging to both block resistance to conventional therapies and promote T cell-based therapies 3, 10, 11 . This article discusses the mechanism of action by which macrophages exert these activities and also the manner in which they may be targeted therapeutically. It describes macrophage diversity and how this promotes tumour progression in primary and metastatic sites. Finally, it also discusses ways to exploit this diversity therapeutically to create an antitumoural microenvironment and to improve chemotherapy, radiotherapy or immunotherapy.
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Macrophages in the TME Macrophages are innate immune cells that populate all tissues 12 and have multiple roles in development, homeostasis and tissue repair 13 . They have different embryological origins (BOX 1) and expand not only in response to infiltration of monocytes but also through local proliferation of tissue-resident macrophage progenitors. Although macrophages express canonical markers such as colony-stimulating factor 1 receptor (CSF1R) in humans and mice, and adhesion G protein-coupled receptor (ADGRE; also known as F4/80) 14 only in mice, studies indicate considerable transcriptomic diversity between macrophage populations even within a tissue. This diversity is consistent with their diverse origin, their adaptation to different tissue niches and their involvement in different pathologies. CSF1R is a transmembrane tyrosine kinase class III receptor that is required for the presence of the vast majority of macrophages 15 . It binds to two ligands, CSF1 and interleukin-34 (IL-34), and regulates macrophage differentiation, proliferation and survival in humans and mice 16 . IL-34 shows overlapping functions with, but no sequence similarity to, CSF1 and binds to a different binding site on CSF1R with a significantly higher affinity than CSF1 (REF. 17 ). IL-34 regulates the development of a subset of macrophages, particularly microglia and Langerhans cells 18 . The role of IL-34 in cancer progression is still largely unknown, although a recent study by Baghdadi et al. 19 showed that IL-34 produced by chemoresistant cancer cells was able to sustain the immunosuppressive functions of TAMs and promote the survival of cancer cells.
Although in the late 19th century the scientific community accepted that tumours were a mixture of malignant and normal cells, it was not until the 1970s that the modern concept of the TME and the idea that immune cells can actually promote cancer growth were introduced 20 . However, even at this time, the dominant view was that macrophages were tumoricidal, as different studies showed that activated macrophages could kill tumour cells in vitro [21] [22] [23] . This view began to change in the early 1990s when several key studies identified a potential role of macrophages in tumour progression by showing correlations of high intra-tumoural density and increased expression of CSF1 with clinical markers of poor prognosis (grade, stage and so on) 24 . In 2001, the genetic ablation of Csf1, and thereby macrophages, in the polyoma middle T (PyMT) model of breast cancer resulted in the inhibition of tumour progression and metastasis, formally proving that macrophages can be pro-tumoural 25 . After this discovery, several independent studies in different cancers confirmed the pro-tumoural role of TAMs and identified several subtypes of TAM in mice and their roles in promoting primary tumour progression and metastasis 3, [26] [27] [28] . Consistent with these experimental mouse models, a meta-analysis of 55 studies of different human cancers indicated that high infiltration of TAMs correlated with poor overall survival in breast, gastric, oral, ovarian, bladder and thyroid cancers but not in colorectal cancer (CRC) 29 (FIG. 1) . The correlation between TAM infiltration and progression in cancer was further confirmed by additional recent meta-analyses in breast cancer, gastric cancer, Hodgkin lymphoma and nonsmall-cell lung cancer (NSCLC) [30] [31] [32] [33] . More specifically, overexpression of CSF1 and the urokinase plasminogen activator (uPA) in CSF1R-positive ovarian cancer cell lines improved their invasive properties 34 . At the clinical level, high serum levels of CSF1 are found in several cancers including metastatic breast cancer 35 , and they correlate with poor prognosis in ovarian and endometrial cancers [36] [37] [38] . In endometrial cancer, epithelial CSF1 synthesis is an independent predictor of survival 39 . In breast cancer, a CSF1 expression signature was described that predicted poor survival 40 . CSF1R expression combined with CD68-positive macrophage infiltration is considered an independent predictor of short progression-free survival in Hodgkin lymphoma 41 . Normal breast and normal ovarian tissues do not express CSF1R and CSF1 (REFS 35, 42 ) but, sometimes, breast and ovarian tumour cells can express this receptor-ligand pair [43] [44] [45] . Nevertheless, expression of CSF1R on cancer cells is rare and is probably due to activation as a result of demethylation of a recently acquired retroviral element in humans; thus, it is not found in mice 46 . These data over the past 18 years, in many different cancer contexts, have supported the conclusion that, in general, TAMs promote tumour progression to malignancy through their interactions with cancer cells (FIG. 1) .
TAMs in solid tumours

Cancer initiation
The activation of key transcriptional factors such as nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α (HIF1α) by chronic inflammation (caused by persistent infection, exposure to irritants or autoimmune disease) or by oncogene activation results in the production of cytokines and chemokines that engage the innate immune system and especially macrophages 47 . Macrophages, in turn, can contribute to cancer initiation by producing pro-inflammatory mediators such as IL-6, tumour necrosis factor (TNF) and interferon-γ (IFNγ), growth factors including epidermal growth factor (EGF) and WNTs, proteases and reactive oxygen species (ROS) and nitrogen species that may create a mutagenic microenvironment 48, 49 . Thus, chronic inflammation, infection or irritation is associated with the initiation of many cancer types such as those in the colon or stomach 50 . Genetic ablation of Stat3 in macrophages causes exuberant inflammation and the formation of invasive tumours in the colon in a mouse model of inflammatory bowel disease 51 . Similarly, the deletion of the anti-inflammatory cytokine IL-10, which signals through STAT3, in macrophages is also associated with tumour initiation and promotion 52, 53 . By contrast, removal of ROS production in myeloid cells, including macrophages, inhibits carcinogenesis in an intestinal cancer model 49 . These chronic inflammatory responses are involved with complicated interactions with the microbiome, changes in dominance of bacterial species and breakdown of mucosal barriers that allow infiltration of pathogenic types 54 . Thus, in animal models, in some cases, the initiation of inflammation-induced cancer can be suppressed by prophylactic treatment with broad-spectrum antibiotics 55 . The role of macrophages in the transition from a benign to a malignant tumour has been studied in only a few cancer models (mammary, skin and pancreatic cancers) 6, 25, 56 and, at least in mammary tumours, premature recruitment of macrophages by overexpression of CSF1 promotes the transition to malignancy 25 . It is thought that in the first stages of tumour formation macrophages are mainly tumoricidal, as they reflect an activated state, although the evidence for this conclusion is limited. What is certain, however, is that, as the tumour grows, T helper 2 (T H 2) cells in the microenvironment that 'educate' macrophages to become pro-tumoural and bias the immune response from a cytotoxic to a supportive role begin to dominate. In mouse models of breast cancer, this state is driven by IL-4 secreted from CD4 + T cells 57, 58 recruited to the tumour through unknown mechanisms.
The transition to malignancy is also exacerbated by macrophages through their production of angiogenic factors, secretion of growth factors and production of proteases.
Tumour progression requires the creation of a vascular network for oxygenation, nutrition and waste disposal. This process, known as the 'angiogenic switch' , is mainly characterized by a dramatic increase in new vessel formation that often involves vessel dilatation and recruitment of perivascular cells [59] [60] [61] . TAMs support these processes by the production of pro-angiogenic factors such as vascular endothelial growth factor A (VEGFA) 62 and angiogenic CXC chemokines (CXCL8 and CXCL12) 63 . Additional factors such as WNT7B, transforming growth factor-β (TGFβ), TNF and thymidine phosphorylase contribute to the angiogenic process by recruitment and activation of endothelial cells or other cells such as fibroblasts or pericytes that further support the generation of vascular networks in the microenvironment 61, 64 . The identification , as their depletion inhibited tumour growth and metastasis 66 . Highly invasive tumour cells are able to move from the primary tumour and intravasate into the blood or lymphatic vessels, where they migrate to distant sites to establish micro-metastases 28 . TAMs are in part responsible for the creation of this invasive TME. TAMs directly help tumour cells to migrate via a paracrine loop between macrophages and tumour cells that involves secretion of EGF family ligands from macrophages and CSF1 from tumour cells, which improves tumour cell invasive properties. TAMs also produce cathepsins and matrix-remodelling enzymes that stimulate this process and increase intravasation by the upregulation of metalloproteinases such as matrix metalloproteinase 9 (MMP9) [67] [68] [69] . Tumour cells are attracted to vessels, where they engage with perivascular TIE2 + macrophages that act as a conduit for the escape of tumour cells in part through expression of VEGFA, which allows bursts of vessel permeability 70 . This tripartite structure consisting of perivascular TAMs, cancer cells that have heightened motility owing to the expression of the invasive isoform of the actin-binding protein mammalian enabled (MENA) and endothelial cells has been called the tumour microenvironment for metastasis (TMEM). Similar structures identified in clinical samples led to the identification of a prognostic clinical score that predicts the chance of metastasis in breast cancer regardless of tumour stage or clinical subtype 71 . Transcriptional profiling of invasive TAMs also revealed upregulation of key components of the WNT and Hedgehog gene families, which are mainly involved in tissue patterning and development in homeostatic conditions 72, 73 . The importance of WNT signalling was confirmed by the identification of WNT7B as one of the key factors secreted by TAMs to promote tumour progression and metastasis, in part through effects on angiogenesis but also through promotion of tumour cell invasion 61 .
TAM-mediated immune suppression
Macrophages can potentially mount a robust antitumoural response, as they are able to directly eliminate cancer cells if properly activated by IFNγ. They also can support the adaptive immune response through presentation of tumour antigens and the production of chemokines and cytokines to recruit and activate cytotoxic CD8 + T cells and natural killer (NK) cells. However, these macrophage activities are restricted by the T H 2 cell dominance in the TME, which profoundly affects macrophage functions such that their phenotypes resemble those involved in tissue development and repair, with a consequent suppression of antitumoural response 3, 13 . TAM-induced immune suppression is mediated by the expression of inhibitory receptors, including non-classical major histocompatibility complex (MHC) class I (MHC-I) molecules such as HLA-E and HLA-G, which are able to negatively modulate the activation of NK cells and T cells by interaction with CD94 and leukocyte immunoglobulin-like receptor subfamily B member 1 (LIR1, also know as ILT2), respectively 74 . TAMs express T cell immune checkpoint ligands, such as PDL1, PDL2, B7-1 (also known as CD80) and B7-2 (also known as CD86), which directly inhibit T cell functions 75, 76 , while also secreting several cytokines, such as IL-10 and TGFβ, that contribute to the maintenance of a strong immunosuppressive microenvironment by inhibiting CD4 + (T H 1 cells and T H 2 cells) and CD8 + T cells and by inducing regulatory T (T reg ) cell expansion. TAM-mediated release of chemokines such as CCL2, CCL3, CCL4, CCL5 and CCL20 further contributes to the recruitment of T reg cells in the TME 3 . TAMs also directly inhibit T cell cytotoxicity through depletion of l-arginine (which is essential for the re-expression of the T cell receptor (TCR) after antigen engagement on T cells) via the release of arginase 1, which metabolizes l-arginine to urea and l-ornithine 3 . Similarly, depletion of tryptophan or production of tryptophan metabolites by indoleamine 2,3-dioxygenase (IDO) expressed by macrophages can inhibit cytotoxic T cells 77, 78 .
TAMs in metastasis
To establish metastasis, invasive cancer cells need to avoid eradication by the immune system, survive in the blood or lymphatic circulation, arrest at a distant site and survive and grow in these often hostile environments. In mouse models of breast cancer and CRC, metastasis-associated macrophages (MAMs) promote these latter steps by increasing extravasation, sending survival and growth signals to tumour cells and inhibiting anti-cytotoxic T cells 5, 79, 80, 81 . Importantly, ablation of these MAMs or blockade of their recruitment results in inhibition of metastasis and in some cases prolonged survival of mice 5, 79, 82 , suggesting that they represent thera peutic targets.
Mechanistically, metastatic cells attract bone marrowderived classical monocytes (that express lymphocyte antigen 6C2 (LY6C)) in mice and CD14 high CD16 negative in humans) through a CCL2-CCR2 mechanism 5 . Once extravasated, these monocytes (called MAM precursor cells (MAMPCs)) differentiate into MAMs 79 through engagement of a chemokine cascade that involves CCR1-CCL3 autocrine signalling 80 . MAMs found in the lungs of mice with metastatic disease are transcriptionally different from resident macrophages and MAMPCs 83 and are characterized by the expression of the markers CD11b, VEGF receptor 1 (VEGFR1; also known as FLT1), CXCR3 and CCR2 (REFS 79, 80 ). Moreover, lung intravital and ex vivo experiments showed that macrophages in the lung interact physically with metastatic cells 84 and support their survival through a vascular cell adhesion protein 1 (VCAM1)-dependent and AKT-dependent mechanism as well as by inducing epithelial to mesenchymal transition by producing TGFβ 85, 86 . Moreover, MAMs and metastatic cancer cells engage in a crosstalk that improves MAM retention in the metastatic foci, which further supports tumour growth through expression of unidentified survival and growth factors 80 . MAMs and their precursors inhibit cytotoxic T cells, suggesting that they are also involved in the maintenance of an immunosuppressive environment that further promotes metastasis 83 . Similar mechanisms have been observed in bone metastasis, in which another class of macrophages -the bone-degrading osteoclasts -are activated by metastatic cells to engage a vicious cycle because the bone resorption liberates entrapped growth factors that further promote metastatic growth 87 . There are currently limited data available on tumoural infiltration in human metastasis, although MAMs that express high levels of VEGFR1 have been identified in lymph node metastases 82 .
Targeting TAMs in cancer therapy
The subpopulations of macrophages with identifiable markers, transcriptomes and phenotypes (FIG. 2) described above are therefore attractive therapeutic targets for combination therapies including standard of care and immunotherapy. In mouse models and clinical contexts, TAMs can synergize with the anticancer therapy or, alternatively, induce pro-tumoural functions by the activation of tissue repair mechanisms. Here, we describe the latest studies reporting dichotomous behaviours of TAMs after standard therapy, and strategies to improve anti-macrophage therapeutics (FIGS. 3,4) .
TAMs in conventional therapies
Radiotherapy. Ionizing radiation is designed to specifically target cancer cells by inducing DNA damage in cells that usually have impaired DNA repair mechanisms. However, the effect of radiotherapy on the TME, and especially on TAMs, is only partially understood 88 . After ablative radiotherapy (single dose of 10 Gy), the innate immune system is activated by inflammatory cytokines, such as IL-1 and TNF, and pro-fibrotic factors such as TGFβ that recruit macrophages with a tissue-reparative phenotype and contribute to tumour recurrence and progression [89] [90] [91] [92] [93] . A recent study by Pinto et al. showed that fractionated cumulative radiation dose regimens similar to those used during cancer treatment induced a pro-inflammatory phenotype in macrophages in vitro but did not alter their ability to promote cancer invasion and cancer angiogenesis 94 . It is becoming a priority to tailor dose and fractionation of radiotherapy in different cancers, as the response elicited by macrophages and the stroma in general can influence the outcome 95 . Consequently, macrophage targeting in combination with radiotherapy is a potential therapeutic strategy to modulate the stroma and allow better tumour killing but, as yet, there are no clinical trials reported.
Chemotherapy. The TME and, in particular, macrophages play an important part in chemotherapy response and resistance [96] [97] [98] . The first observation that suggested a Tumour-associated macrophages (TAMs) that express canonical macrophage markers in the mouse (CD11b, colony-stimulating factor 1 receptor (CSF1R) and adhesion G protein-coupled receptor (ADGRE; also known as F4/80)) can be polarized to adopt different pro-tumoural functions depending on the environment, as indicated. These activities promote tumour initiation through inflammation, tumour progression to malignancy via increasing angiogenesis, immunosuppression, invasion, intravasation and at distant sites tumour cell extravasation and persistent growth. Each of these functions is performed by a subpopulation of macrophages with a different transcriptome and cell surface markers, as indicated. EGF, epidermal growth factor; MARCO, macrophage receptor with collagenous structure; MHC-II, major histocompatibility complex class II; TIE2, angiopoietin 1 receptor; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor 1.
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Immune + role of TAMs in mediating resistance to chemotherapy was the demonstration that CSF1 inhibition was able to reverse chemoresistance of breast cancer cell lines in xenograft mouse models 99 . DeNardo 100 et al. confirmed and extended this initial observation and showed that tumour biopsy samples from cancer patients who received neoadjuvant therapy had a much larger infiltrate of CD45 + CD11b + CD14 + macrophages than those from patients who received only surgery. They also demonstrated that treatment of PyMT mice with paclitaxel in combination with anti-CSF1R antibodies significantly reduced tumour burden and vessel density and increased cytotoxic T cell infiltration compared with treatment with paclitaxel alone.
TAMs are responsible for the increased production of cathepsins that leads to increased lymphangiogenesis and metastasis after paclitaxel treatment 101, 102 . Upon 5-fluorouracil treatment of CRC, TAMs release the diamine putrescine, which confers on cancer cells resistance to apoptosis in a JNK-dependent and caspase 3-dependent manner 103 . Doxorubicin, another chemotherapeutic agent, can also induce the selective accumulation of perivascular MRC1 + TAMs around the blood vessels. These perivascular TAMs promoted recurrence after therapy partly through the expression of VEGF and subsequent increased angiogenesis. Selective targeting of the recruitment of this perivascular TAM population by CXCR4 blockade showed reduced tumour relapse after chemotherapy, suggesting that this targeting strategy is of clinical utility 63 .
Immunotherapy. Mutated tumour cells can express tumour antigens as a product of oncogenic viruses, differentiation antigens or tumour-specific mutations (tumour neo-antigens). The production of neo-antigens is not equal across tumour types, with tumours such as melanoma and lung cancers expressing the highest rate of neo-antigens, and haematological malignancies (acute myeloid leukaemia (AML), acute lymphoblastic leukaemia and chronic myelogenous leukaemia) expressing the lowest 104 . T cells are able to recognize tumour antigens loaded to the MHC on the cancer cell through binding to the TCR; however, to get completely activated, they require interaction of CD28 with co-stimulatory B7 molecules (CD80 and CD86) expressed on the antigen-presenting cell (APC). Cancer cells do not express B7 molecules, and so, without a second stimulatory signal provided by other APCs (such as dendritic cells and macrophages) recruited by inflammatory signals, the antitumoural T cell response will not start.
The identification of tumour antigens led to the development of several tumour vaccination strategies in the 1980s, in which tumour-derived antigens (DNA or peptides) were injected together with cytokines in order to enhance the immunological response. Results from these trials, however, were not as striking as expected 105 , suggesting that the regulation of T cell activation in the tumour is complex. Both preclinical and clinical studies indicated that tumours are infiltrated by immunosuppressive cells (T reg cells, TAMs, cancer fibroblasts and myeloid-derived suppressor cells) and that they are exposed to an immunosuppressive cytokine milieu (IL-10 and TGFβ).
With this increasing understanding, the immunotherapy field has had a rapid expansion particularly with the discovery of immune checkpoint inhibitors, such as mAbs against CTLA4 and PD1, whose main function is to remove the 'brakes' on T cells, allowing an effective antitumoural immune response 106 . One anti-CTLA4 (ipilimumab) and two anti-PD1 (pembrolizumab and nivolumab) neutralizing antibodies are currently US Food and Drug Administration-approved for the treatment of several cancers including melanoma, advanced renal carcinoma, gastric cancer, NSCLC and CRC; hundreds of clinical trials on multiple solid cancers are ongoing to evaluate their efficacy. Although efficacy in melanoma and some other cancers is high, especially when anti-CTLA4 and anti-PD1 therapies are combined, in many other cancers, only a small fraction of treated patients respond. One hypothesis is that the efficacy of checkpoint inhibitors could be improved by the modulation of immunosuppressive cells such as TAMs. TAMs express high levels of PDL1 and PDL2, as well as PD1. PD1 expression in TAMs also negatively correlates with the ability of these cells to phagocytose cancer cells, and therefore, TAM-specific PD1 inhibition reduces tumour growth 107 . Moreover, CSF1 expression correlates with accumulation of CD8 + T cells and CD163 + TAMs in melanoma, and anti-PD1 and anti-CSF1R combination therapy induced regression of melanoma in preclinical studies 108 . Clinical trials combining checkpoint inhibitors and anti-TAM agents (such anti-CSF1R antibodies; see below) are currently ongoing in different solid tumour contexts [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] .
Methods of TAM targeting
TAM depletion. The dependence of macrophages on CSF1R signalling makes this an attractive target to selectively deplete macrophages. Consequently, different antibodies and small molecules mainly targeting CSF1R are being studied in different clinical trials both as monotherapies or in combination with standard therapy or immunotherapies.
The small molecules under clinical development and study are PLX3397, JNJ-40346527, PLX7486, ARRY-382 and BLZ945. Preclinical studies showed that PLX3397, or pexidartinib, reduced the number of tumour-associated microglia and glioblastoma invasion 120, 121 ; in glioma mouse models, the tyrosine kinase inhibitors dovitinib and vatalanib increased sensitivity to PLX3397. PLX3397 was tested in a phase I dose-escalation clinical trial followed by a phase II extension study in patients with advanced tenosynovial giant cell tumours 122 , a tumour type characterized by the high expression of CSF1 and CSF1R 123, 124 . Results from the phase I and phase II studies indicated that PLX3397 was tolerated at a dose of 1,000 mg, and in the extension study, 12 out of 23 patients (52%) showed antitumour responses after treatment 122 . In a phase II study in patients with recurrent glioblastoma, PLX3397 treatment was tolerated, and PLX3397 was able to pass the blood-tumour barrier; however, PLX3397 treatment did not show improvement in 6-month progression-free survival values when compared with those of the group receiving radiotherapy and temozolomide 125 . JNJ-40346527, another kinase inhibitor, was tested in a phase I/II study on 21 patients with relapsed or refractory Hodgkin lymphoma. One patient showed complete remission, and eleven patients showed stable disease 126 . Several phase I clinical trials are ongoing with additional CSF1R inhibitors: PLX7486 is being tested as a single agent in patients with advanced-stage solid tumours (tenosynovial giant cell tumour and tumours of any histology with activating mutations in brain-derived neurotrophic factor (BDNF)) 127 , and ARRY-382 is currently involved in two phase I clinical trials 128,111 in patients with metastatic disease and advanced-stage solid tumours. BLZ945 was reported to alter macrophage polarization and to block glioma progression 129 with promising results when used in combination with inhibitors of insulin-like growth factor 1 receptor (IGF1R) and phosphoinositide 3-kinase (PI3K) 130 and is currently under assessment in a trial in advanced-stage solid tumours as a single agent or in combination with the anti-PD1 antibody PDR001 (REF.
112
).
Figure 3 | Targeting and reprogramming TAM pro-tumoural activities.
The figure shows pro-tumoural tumour-associated macrophage (TAM) activities (angiogenesis, immune escape, dissemination, and so on) that have been targeted in either preclinical models or therapeutic trials in humans. The strategies fall into six main groups: (1) blocking pro-tumoural functions such as those that promote intravasation, angiogenesis or metastatic cell extravasation and/or persistent growth; (2) promoting phagocytosis of tumour cells by macrophages; (3) using checkpoint or anti-immunosuppressive cytokine and/or protein inhibitors to allow cytotoxic T cell activity; (4) reprogramming TAMs to become antitumour macrophages either directly through tumour cell killing or by T cell activation; (5) inhibiting the tumour suppressive microenvironment; and (6) inhibiting recruitment of the monocytic progenitors of TAMs; CSF1, colony-stimulating factor 1; CSF1R, CSF1 receptor; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; MARCO, macrophage receptor with collagenous structure; miRNA, microRNA; NK, natural killer; PD1, programmed cell death 1; PDL1, PD1 ligand 1; PI3Kγ, phosphoinositide 3-kinase-γ; SIRPα, signal regulatory protein-α; TGFβ, transforming growth factor-β; TLR, Toll-like receptor; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand; T reg cell, regulatory T cell; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. + macrophages and T cell TME composition in patients with advanced-stage diffuse-type giant cell tumours treated with RG7155 as monotherapy or in combination with paclitaxel 124 . These promising results led to a dose-escalation phase I clinical trial in 12 patients with tenosynovial giant cell tumours to investigate the clinical benefit of RG7155; the compound showed no dose toxicity, and common adverse effects reported were facial oedema, asthenia and pruritus. In the dose-expansion phase, out of the 28 patients tested, 24 patients (86%) showed an objective response, and 2 (7%) achieved a complete response 131 Overall, these preliminary results suggest that targeting the CSF1-CSF1R axis could be a promising strategy. Indeed, in tumours overexpressing CSF1, such as the synovial giant cell tumours, it is likely that this approach will be advanced as an effective treatment. Nevertheless, reported toxicity has limited dose escalation, as it is problematic to deplete all macrophages from the body for a long period of time.
Nature Reviews | Drug Discovery
Another therapeutic strategy is to selectively deplete TAMs and not the other components of the stroma. An example of this strategy is the use of bisphosphonates. These inorganic compounds are stable, and their structure is identical to pyrophosphatases of the bone matrix, so they can be metabolized rapidly by osteoclasts and inhibit their resorption. Moreover, they are already in use as anticancer agents for the treatment of haematological and solid malignancies 137, 138 . Bisphosphonates are mainly subdivided into two classes on the basis of their structure and mechanism of action: clodronate, etidronate and tiludronate belong to the first group, and alendronate, ibandronate, pamidronate, risedronate and zolenodrate belong to the second group. At the preclinical level, bisphosphonates exhibited direct and indirect antitumour properties. They are reported to inhibit cancer cell proliferation, induce tumour cell apoptosis, block angiogenesis, inhibit cell adhesion and invasion and interfere with immune surveillance through activation of γδ T cells 139 . Different studies showed that bisphosphonates are also able to inhibit proliferation, migration and invasion of macrophages, causing apoptosis 140, 141 . They, however, mainly affect osteoclasts that share the same lineage with macrophages and thus have been used in preclinical bone metastasis models.
A more directed approach when using bisphosphonates is to encapsulate clodronate, for example, in liposomes (clodrolip), which are preferentially taken up by macrophages owing to their phagocytic activities. This treatment reduced macrophage tumour infiltration in experimental models of bone metastasis from lung cancer 142 and lung metastasis from breast cancer 79 and thereby limited metastatic outgrowth. Similar results were obtained in mice injected with human melanoma cells, in which clodrolip reduced tumour mass and angiogenesis 143 . Clodrolip in combination with anti-VEGF mAbs showed antitumour properties in mice injected with teratocarcinoma and rhabdomyosarcoma cells, with a significant reduction of TAM infiltration 144 . Moreover, in mouse models of metastatic hepatocellular carcinoma, the combination treatment with clodrolip and sorafenib caused decreased tumour burden, angiogenesis and metastasis 145 . Clodrolip was also tested in dogs with spontaneous soft tissue sarcomas, in which it depleted CD11b + macrophages in tumours and decreased IL-8 serum levels, although the antitumour properties of the treatment were not significant 146 . Zoledronic acid, another bisphosphonate, reduced tumour burden in a mouse model of bone metastases from breast cancer 147 and to modulate the TME by reducing the number of TAMs and their polarization status 148 . Recently, Comito et al. 149 demonstrated that treatment with zoledronic acid impairs macrophage polarization, reduces macrophage-induced angiogenesis and decreases tumour invasion in prostate cancer. Current studies using nanotechnology are trying to optimize the delivery of bisphosphonates by their encapsulation in stealth liposomes or in PEGylated nanoparticles; preclinical tests were promising, showing better antitumoural activity and lower TAM numbers than those seen with treatment with free bisphosphonates [150] [151] [152] . At the clinical level, clodronate and zoledronic acid were tested in several clinical trials on a variety of different cancers with inconsistent results that suggest the need to optimize better combination treatments and for longer clinical trials, as discussed in several metaanalyses 153, 139, 154 . There are currently two ongoing clinical trials evaluating the effect of zoledronic acid in triple-negative breast cancer 155 and stage IIIb and IV lung cancer 156 . Clodronate is also being tested in different clinical trials as a neoadjuvant agent in patients with breast cancer 157 and in combination with chemotherapy and hormonal therapy 158 ; additional trials include a clodronate-chemotherapy combination treatment in patients with metastatic refractory prostate cancer 159 . Trabectedin is a tetrahydroisoquinoline alkaloid that was initially isolated from the Caribbean tunicate Ecteinascidia turbinata 160 . It is an anti-neoplastic drug approved in Europe, Russia and South Korea for the treatment of advanced-stage tissue sarcoma and platinum-sensitive relapsed ovarian cancer in combination with PEGylated liposomal doxorubicin [161] [162] [163] . Trabectedin, in addition to targeting tumour cells, specifically induces apoptosis of monocytes and macrophages in the tumour by the activation of caspase 8 through a TNF-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10)-dependent mechanism 164 . These results suggested that the apoptotic receptor family TRAIL could be a therapeutic target to selectively kill immune cells and, especially, macrophages. A recent report by Liguori et al. 165 explored this hypothesis and demonstrated that monocytes and macrophages express the functional TRAIL receptors TRAILR1 (also known as TNFSF10A) and TRAILR2 (also known as TNFRSF10B), whereas neutrophils and lymphocytes express the non-functional decoy receptor TRAILR3 (also known as TNFRSF10C). Interestingly, human TAMs in mammary, hepatic and colon carcinoma, but not resident tissue macrophages, express functional TRAILRs 165 , making these receptors interesting targets for therapy 166 .
Inhibition of TAM recruitment. TAM expansion in the tumour is often mediated by monocytic recruitment through the CCL2-CCR2 axis. CCL2 is a potent chemo attractant for monocytes, T cells and NK cells 167 , and several mouse studies have demonstrated a role for it and other chemokines in macrophage accumulation in the tumours [168] [169] [170] [171] . CCL2 released by tumour cells recruits classical monocytes that express the receptor CCR2 to the tumour sites, and inhibition of CCL2 correlates with reduced tumour burden and metastasis in different experimental models of prostate, breast, lung and liver cancers and melanoma 172 . However, withdrawal of anti-CCL2 treatment accelerated lung metastasis in mouse models of breast cancer and resulted in death of mice owing to a rebound in monocyte recruitment, which raised important concerns about the long-term efficacy of this approach 173, 174 . However, high levels of CCL2 in serum, as well in the tumour, are associated with poor prognosis in different types of tumours, such as breast cancer 175, 176 . For these reasons, several CCL2-neutralizing antibodies are now being tested in clinical trials. The two main drugs currently tested are carlumab (CNTO 888), an anti-CCL2 mAb, and PF-04136309, a small molecule inhibitor that targets CCR2.
Carlumab is a human immunoglobin G1κ antibody that binds to CCL2. In prostate cancer mouse models, systemic injection of the antibody reduced tumour growth, infiltration of CD68 + macrophages and vascular density 177, 178 . CCL2 inhibition was also able to improve the effect of paclitaxel and carboplatin therapies in mouse models of ovarian cancer 179 . A phase I clinical trial was carried out in 2013 to assess tolerance to different doses of carlumab in 44 patients with different solid tumours 180 . The results indicated that CCL2 levels were only partially suppressed by carlumab, with an increase of free CCL2 after treatment over the pretreatment baseline of more than 1,000-fold 173 . A phase II clinical trial was then carried out in 46 patients with castration-resistant metastatic prostate cancer, with no reported therapeutic efficacy of carlumab 181 . The CCR2 small molecule inhibitor PF-04136309 was recently assessed in a phase Ib non-randomized trial in patients with locally advanced pancreatic cancer in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil); 47 patients were treated and 8 patients received only FOLFIRINOX, while the remaining patients received FOLFIRINOX and PF-04136309. Results showed that PF-04136309 treatment in combination with FOLFIRINOX was safe and well tolerated compared with chemotherapy alone. Patients treated only with FOLFIRINOX did not show an objective response to the treatment. By contrast, in the PF-04136309 plus FOLFIRINOX group, 16 of the 33 patients, who underwent repeated imaging assessments, had an objective tumour response, and 32 of those patients achieved local tumour control 182 . These trials, however, were largely disappointing and indicated that much more biological knowledge is needed to achieve effective inhibition of monocyte recruitment. For example, CCL2-CCR2 signalling is required for monocyte egress from the bone into the blood, and CCL2 inhibition results in a severe depletion of monocytes. This depletion is recognized, and the organism attempts to overcome this deficiency with a dramatic elevation in CCL2 concentration, which in turn prevents efficacy of the reagents. In our own studies using genetic ablation, we have demonstrated the requirement for CCR2 to recruit monocytes to the primary tumour in the PyMT model but that in the absence of CCR2 in monocytes this recruitment is completely overcome by unknown redundancy mechanisms 4 . In addition, there may be compensatory proliferation of tissue-resident macrophages if recruitment is blocked 6 . Therefore, much more biological understanding is required before this approach to selectively inhibit monocyte recruitment to the tumour or its metastatic derivatives is likely to be effective. Indeed, it may be better to explore inhibition of molecules required for retention of monocytes, such as CCL3, or molecules that induce their differentiation 4, 80 .
Reprogramming of TAMs
Despite generally being pro-tumoural, TAMs can, depending on context, be tumoricidal and also suppress tumour growth by activating immune responses 183 . This suggests that macrophage plasticity can be therapeutically exploited to restore antitumour properties to TAMs 184 . Indeed, it might indicate the paucity of the approach of targeting all macrophages, as both protumoural and antitumoural macrophages will be depleted. Instead, macrophage reprogramming is a targeting strategy that provides an opportunity to rebalance the microenvironment immune infiltrate therapeutically from a pro-tumoural one to one that actively rejects the tumour in synergy with T cell-enhancing drugs such as checkpoint inhibitors. It also eliminates the drawbacks and long-term toxicity of ablation of all macrophages, such as that seen in the case of anti-CSF1R therapeutics discussed above. Different methods are currently being tested at the preclinical and clinical levels, as discussed below.
Anti-CD47 antibodies. CD47 is a ubiquitous protein that regulates cell migration, axon extension, cytokine production and T cell activation [185] [186] [187] [188] . CD47 interacts with thrombospondin 1 and signal regulatory protein-α (SIRPα; also known as SHPS1), which are mainly expressed by myeloid cells, including dendritic cells and macrophages 189 . In the latter case, CD47 inhibits phagocytosis by the prevention of myosin IIA accumulation at the phagocytic synapse 190 . The result of this interaction is a 'do not eat me' signal that prevents phagocytosis of autologous cells in homeostatic conditions. This mechanism is tightly regulated, and it is mainly activated in pro-inflammatory conditions, as CD47-null mutant mice show a phenotype against self only during inflammatory conditions 191 . CD47 is overexpressed in a variety of tumours [192] [193] [194] [195] through the activation of CD47-specific super-enhancers 196 . It is involved in tumour invasion, metastasis and, more importantly, inhibition of phagocytosis by the innate immune system by interacting with SIRPα 195 expressed on phagocytes. Several preclinical studies in xenograft mouse models demonstrated that CD47 inhibition is an effective strategy for tumour therapy [197] [198] [199] , as it enables killing and phagocytosis of tumour cells by macrophages. The role of CD47 in the inhibition of phagocyte-mediated killing was confirmed recently in human small-cell lung and ovarian cancer cell lines 200, 201 . Highly phagocytic bone marrow-derived macrophages, in which SIRPα had been inhibited by injection of antitumour antibodies against MUC1 and EGF receptor (EGFR) (cetuximab), could effectively reach the tumour and engulf human lung carcinoma A549 cancer cells, causing tumour regression. However, the antitumoural effect observed was then lost owing to their differentiation to TAMs 202 . At the moment, there are two anti-CD47 mAbs (Hu5F9-G4 and CC-90002) and one soluble recombinant SIRPα-crystallizable fragment (Fc) fusion protein (TTI-621) currently being tested in phase I clinical trials. Hu5F9-G4 showed promising results at the preclinical level in human AML 203 and in paediatric brain tumours 204 . There are currently four ongoing clinical trials on different solid and haematological malignancies [205] [206] [207] [208] to study the safety of Hu5F9-G4 in patients. Preliminary results from the NCT02216409 trial indicated that Hu5F9-G4 was tolerated with reversible side effects observed such as anaemia, headache, nausea and retinal toxicity 209 . Two trials assessing CC-90002 210,211 have been initiated in patients with haematological malignancies, but results have not been published yet.
TTI-621 is a fully human recombinant protein that blocks the CD47-SIRPα axis and improves killing of cancer cells. A recent study investigated the efficacy of TTI-621 in aggressive AML and B cell lymphoma xenografts; TTI-621 successfully improved macrophagemediated phagocytosis of cancer cells but not normal cells. Moreover, in vivo data suggested that TTI-621 treatment was able to control the growth of haematological and solid tumours in mouse xenografts models 212 . TTI-621 is currently being tested at the clinical level in two ongoing clinical trials on haematological and multiple solid tumours 213, 214 . Toll-like receptor agonist. Toll-like receptors (TLRs) are innate immunity pattern recognition receptors that have fundamental roles in the activation of the innate immune response 215 . Activation of TLR by bacterial particles (such as lipopolysaccharide) and viral nucleic acids (RNA or DNA) polarizes macrophages towards a pro-inflammatory phenotype. For this reason, different TLR synthetic ligands have been tested in cancer models in order to assess their efficacy in the phenotypic switch of TAMs to tumoricidal macrophages in the TME 216 .
In an orthotropic mammary tumour mouse model, intra-tumoural delivery of TLR7 and TLR9 agonists caused increased monocyte infiltration in the tumour and macrophage repolarization 217 ; similar results were obtained with an agonist of both TLR7 and TLR8 (3M-052) that induced macrophage repolarization and improved tumoricidal activity in melanoma 218 . In preclinical models, the TLR7 ligand imiquimod, the only TLR agonist approved for clinical use, showed antitumoural activity in basal cell carcinoma, melanoma and breast cancer skin metastases [219] [220] [221] [222] . Two TLR7 ligands (imiquimod and 852A) and one TLR9 ligand (IMO-2055) are being tested for their antitumoural properties in clinical trials. Imiquimod has been tested on several cancers: in a prospective clinical trial, topical treatment of skin metastases from breast cancers with imiquimod was well tolerated, and responders showed histological tumour regression and increased lymphoid immune infiltration 221 . 852A has been tested in five clinical trials in melanoma, leukaemia and gynaecological cancers [223] [224] [225] [226] [227] . A phase I clinical trial on patients with advanced-stage cancer showed that treatment with 852A three times per week for 2 weeks was well tolerated, with reversible side effects 228 .
IMO-2055 has been tested in CRCs and head and neck, lung and renal cancers [229] [230] [231] [232] [233] . Results from a clinical trial in patients with advanced metastatic NSCLC showed good tolerability and potential antitumoural activity of IMO-2055 when used in combination with erlotinib and bevacizumab 234 .
Anti-CD40 antibodies. CD40 is a receptor that belongs to the TNF receptor superfamily, and it is expressed by APCs such as monocytes, macrophages, dendritic cells and B cells 235 , but it can be expressed by endothelial and epithelial cells as well. The natural ligand of CD40 is CD40L, which is mainly expressed by CD4 + T cells, basophils and mast cells 236 . The CD40-CD40L interaction upregulates the expression of MHC molecules and the production of pro-inflammatory cytokines, such as IL-12, which primes naive CD4 + and CD8 + T cells into T helper and cytotoxic cells, respectively. Agonistic anti-CD40 antibodies exert tumour inhibitory effects in several tumour mouse models, an observation that has opened the way for the development of clinically relevant anti-CD40 antibodies.
Interestingly, TAM treatment with CD40 agonists in combination with anti-CSF1R antibodies results in a profound TAM reprogramming before their depletion; these reprogrammed TAMs create a pro-inflammatory environment that elicits effective T cell responses even in tumours that were non-responsive to immune checkpoints inhibitors 237, 238 . Two agonistic anti-CD40 antibodies are being tested in clinical trials: CP-870,893 and RO7009789. In a phase I dose-escalation study, 29 patients with solid tumours were treated with a single intravenous dose of CP-870,893; common adverse effects included cytokine release syndrome and alterations of immune cell number but, in general, the treatment was well tolerated, and CP-870,893 led to an objective response and antitumour activity 239 . CP-870,893 treatment in combination with carboplatin and paclitaxel was tested in 32 patients with advanced-stage solid tumours in another phase I trial; 6 out of 30 evaluable patients showed partial response to treatment and depletion of B cells together with upregulation of immune co-stimulatory molecules 240 . Similar results were obtained in patients with malignant pleural mesothelioma treated with CP-870,893 in combination with cisplatin and pemetrexed 241 and in patients with advanced-stage pancreatic ductal adenocarcinoma 242 . RO7009789 is being studied in four ongoing clinical trials on advanced-stage solid tumours 114, [243] [244] [245] . Histone deacetylase inhibitors. Histone deacetylases (HDACs), of which there are 18 in mammals, are divided into four classes 246, 247 . HDACs are responsible for removing the acetyl groups on histones, a crucial process in epigenetic regulation of gene expression. TMP195, a specific inhibitor of class IIA HDACs 248 , can modify the epigenomic profile of monocytes and macrophages, resulting in, for example, altered CCL1 and CCL2 expression in monocytes and a pro-inflammatory phenotype. In a model of luminal B-type breast cancer, intraperitoneal injection of TMP195 increased infiltration of CD11b + myeloid cells from blood into the tumour, where they differentiated into antitumoural macrophages 249 . This resulted in reduced vessel permeability as well as in reduced vasculature and tumour cell proliferation. Moreover, the antitumour macrophage phenotype induced by TMP195 treatment increased the efficacy and durability of both standard chemotherapeutic regimens (carboplatin and paclitaxel) and immunotherapy (anti-PD1 antibodies). These findings suggest that class IIA HDAC inhibitors can selectively reprogramme monocytes and macrophages in the tumour and open interesting therapeutic opportunities, although it remains to be seen whether targeting this HDAC subclass will be sufficiently specific if given systemically to patients.
Anti-MARCO antibody therapy. The macrophage receptor with collagenous structure (MARCO) is a pattern recognition receptor that belongs to the class A scavenger receptor family. MARCO is mainly expressed by macrophages 250 , and its expression was linked to poor prognosis in breast cancer 251 . A recent report by Georgoudaki et al. 252 showed that MARCO is expressed in TAMs of patients with breast cancer and metastatic melanoma. MARCO neutralization with antibodies inhibits tumour growth and metastasis in the 4T1 mammary carcinoma model. Similarly, using a B16 melanoma mouse model, treatment with an anti-MARCO antibody inhibited tumour growth and improved the effects of anti-CTLA4 immunotherapy 252 . The antitumour activity of anti-MARCO therapy was dependent on the ability of the Fc portion of the anti-MARCO antibody to engage with the inhibitory Fc receptor FcγRIIB, as previously demonstrated with other mAb-mediated reprogramming strategies 253 . This study highlights the feasibility of antibody-mediated reprogramming of macrophages by using TAM-derived targets and stresses the importance of the correct design of the antibodies, especially the Fc region, for future clinical interventions.
PI3Kγ inhibitors. PI3Ks are involved in almost all types of signalling in cells 254 . There are several subclasses of PI3K, of which class 1B PI3Kγ is mainly expressed in haematopoietic cells. Mice that lack PI3Kγ expression show impaired recruitment of inflammatory cells, mainly macrophages and neutrophils 255 . Kaneda et al. 256 showed that PI3Kγ is a key regulator of the tumour immune suppression exerted by TAMs; genetic and pharmacological inhibition of this target induced the expression of MHC class II (MHC-II) molecules together with upregulation of IL-12 and decreased secretion of IL-10. As a result, the inhibition of PI3Kγ in TAMs caused recruitment of cells associated with antitumour adaptive immunity and tumour growth inhibition. At the clinical level, patients with head and neck and lung cancers with low PI3Kγ activity had a better prognosis and longer overall survival, suggesting that PI3Kγ could be a potential future therapeutic target.
Inhibition of microRNA activity. MicroRNAs (mi RNAs) are small non-coding RNAs that regulate transcription and translation in a sequence-specific manner, and their maturation is regulated by the RNase-III enzyme DICER 257 . A recent study showed that inhibition of DICER in macrophages affects TAM programming and is associated with tumour regression and altered infiltration of immune cells 258 . DICER inhibition reprogrammed TAMs to express an IFNγ-STAT1 signature and to become antitumoural. DICER inhibition in TAMs was also associated with a better response to immunostimulatory antibodies 258 . These data raise the possibilities of identification and targeting mi RNAs to repolarize TAMs.
Conclusions and perspectives
TAMs represent a heterogeneous population with defined functions that differ between primary and metastatic tumours. Immune cell infiltrates also vary according to tumour type and, thus, dynamic interactions between TAMs and other immune cells are likely to vary according to cancer type and stage of progression. In addition to pro-tumoural effects, TAMs can also have antitumour effects that in some cases might be dominant. Consequently, it is necessary to understand tumour heterogeneity and how it evolves during the progression to malignancy and also following therapy. It is also judicious to realize that much of these data derive from mouse models, and that there is scant knowledge except at the most descriptive level about TAMs in human cancers.
Despite these caveats, given the consensus that TAMs are overall pro-tumoural, several anti-TAM strategies aimed at depletion (such as CSF1R inhibitors), reprogramming (such as PI3Kγ and HDAC inhibitors) and targeting of functional molecules (such as arginase 1 and Fc receptors) are in preclinical and clinical trials (FIG. 4) . Despite these advances, each strategy needs further investigation, as they all have limitations. For example, the general depletion of monocytes and macrophages exerted by CSF1R inhibitors is not TAMspecific and thus has substantial toxicity over time 259 . Furthermore, given the complexity of TAM populations, there is growing awareness that the functioning of macro phages and dendritic cells is required for anti-PD1 (REF. 260 ) and anti-CTLA4 therapies 261 , respectively. Thus, potential alternative strategies would be to ablate TAMs transiently, followed by recovery periods during which monocytes could be recruited into the tissue to promote antitumour immune reactions before differentiating into pro-tumoural TAMs. This strategy is attractive, but it will require a careful timing and a better knowledge of the immune interactions ongoing in all phases of tumour formation 262 . Therefore, going forward, a better strategy would be to specifically target pro-tumoural macrophages and enhance the activity of antitumoural ones or to repolarize existing ones to have antitumoural activities. In this context, TAM therapy aimed at the functional modulation of TAM subpopulations through the use of mAbs showed promising preclinical results. This strategy, combined with the use of Fc receptor inhibitors, seems to be the most promising one for the modulation of the TME, as macrophages are able to rapidly take up anti-PD1 antibodies through their Fc receptors, limiting the efficacy of the checkpoint inhibitors. Thus, it will be fundamental to identify TAM-specific targets (such as MARCO) to improve therapy specificity. Other methods of macrophage manipulation have been introduced, including macrophages that express chimeric antigen receptors (CAR-macrophages) and designer supramolecules -for example, against CD47 and CSF1R -that home to SIRPα-expressing macrophages and amplify immune responses, limiting tumour growth 263, 264 . These exciting strategies will need considerable refinement to reach human applications but may well be the wave of the future.
Another interesting approach might also be to understand the interactions between the microbiome and macrophages. Such a concept is based on recent studies suggesting that manipulation of the microbiome alters cancer incidence as well as responses to therapy 265, 266 . As macrophages are sentinel cells for changes in the microbiota, usually through TLR engagement, understanding the exact nature of these interactions and their consequences could potentially help tailor an anticancer microbial cocktail 267 . Another strategy is to target cancer-associated myeloid immature progenitors 268 , which are cells that are mainly found in the blood of cancer patients and that are thought to be the progenitors of tumour-infiltrating myeloid cells. Several studies indicated that these immature cells have intrinsic immunosuppressive functions in vitro and therefore could represent a very promising target in combination with immunotherapy 269 . However, again, the challenge is to identify specific markers that will allow the selective targeting of these abnormally expanded immature populations, as there are currently not enough markers available to distinguish them from mature myeloid cells.
To improve all therapeutic modalities, a thorough understanding of the TME is required in humans and in different cancer types, including the identification of specific populations of cells, compensatory mechanisms between cells of the innate system and their mechanisms of immunosuppression and tissue repair. In this context, the extensive use of single-cell RNA sequencing, multiplex immunohistochemistry and mass cytometry will considerably increase our knowledge, and it will allow the selection of novel TAM targets for the modulation of the TME to improve therapy.
